Abstracts tagged "osteonecrosis"

Abstract Number: 1626 • ACR Convergence 2021
Use of Total Hip Arthroplasty in Patients Under 21 Years Old: A U.S. Population Analysis
J. Alex Gibbons¹, Cynthia Kahlenberg¹, Deanna Jannat-Khah¹, Susan Goodman¹, Lisa Mandl¹, Peter Sculco¹, Stuart Goodman², Mark Figgie¹ and Bella Mehta³, ¹Hospital for Special Surgery, New York, NY, ²Stanford University, Stanford, CA, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Total hip arthroplasty (THA) is a treatment option for young patients with severe hip pathology due to congenital, developmental, rheumatologic, traumatic, and other acquired…
Abstract Number: 135 • 2020 Pediatric Rheumatology Symposium
Use of Intravenous Pamidronate in Pediatric Leukemia Patients with Osteonecrosis Results in Reduced Pain and May Halt Osteonecrosis Progression
Paivi Miettunen¹, Chloe Stephenson ¹, Seemab Haider ¹, Seamus Stephenson ², Vijay Moorjani ² and Rondald Anderson ², ¹University of Calgary, Calgary, Alberta, Canada, ²University of Calgary, Calgary, Canada
Background/Purpose: Osteonecrosis has emerged as debilitating complication of acute pediatric lymphoblastic leukemia (pALL), with severe pain and poor functional outcome. Patients with ON of weight…
Abstract Number: 1578 • 2019 ACR/ARP Annual Meeting
Factors Implicated in the Development of Early Osteonecrosis in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna Gladman ², Jiandong Su ³ and Murray Urowitz ³, ¹University Health Network, University of Toronto, Toronto, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Osteonecrosis (ON) complicates approximately 15-20% of patients with systemic lupus erythematosus (SLE) on an average of six years after diagnosis. However, a small subgroup…
Abstract Number: 1790 • 2016 ACR/ARHP Annual Meeting
Accrual of Disease Comorbidities over 8 Years in a Multicentre Inception SLE Cohort
Murray Urowitz¹, Dafna D Gladman², Nicole Anderson³, Jiandong Su⁴ and The Systemic Lupus International Collaborating Clinics (SLICC) Group, ¹Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: The annual accrual of comorbidities in patients with SLE is not well described. We report the annual occurrence of these features in an inception…
Abstract Number: 260 • 2012 ACR/ARHP Annual Meeting
Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program
Marc C. Hochberg¹, Steven B. Abramson², David S. Hungerford³, Edward McCarthy⁴, Eric P. Vignon⁵, Michael D. Smith⁶, Leslie Tive⁷, Kenneth M. Verburg⁶ and Christine R. West⁸, ¹Department of Medicine, University of Maryland, Baltimore, MD, ²Dept of Rheumatology/Medicine, NYU Langone Medical Center, New York, NY, ³Department of Ortho Surgery, Johns Hopkins University, Baltimore, MD, ⁴Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Rheumatology 2B, Centre Hospitalier, Pierre Benite, France, ⁶Pfizer, Inc., Groton, CT, ⁷Arthritis, Pfizer Inc, New York, NY, ⁸Clinical Sciences, Pfizer, Williamston, MI
Background/Purpose: Tanezumab (TNZ) has been shown to be efficacious for pain and function in patients with hip and knee osteoarthritis (OA). Unexpected reports of adverse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].